NGNE 241220 22.50C (NGNE241220C22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

NGNE241220C22500

Watchlist

0.40
+0.15+60.00%

15min DelayClose Nov 21 16:00 ET

0.40High0.16Low

Intraday

5D
Daily

News

Neurogene Adjusts Clinical Trial After Setback
TipRanks55minutes ago
Express News | Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome
Reuters16:12 ET
Express News | Neurogene Inc - FDA Allows Neurogene to Proceed With Phase 1/2 Trial Using 1E15 Vg Dose
Reuters16:05 ET
Express News | Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies
Reuters16:05 ET
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Moomoo NewsNov 21 08:31 ET · Ratings
Express News | Neurogene Inc : Stifel Cuts Target Price to $46 From $60
ReutersNov 21 07:21 ET

Comments

Zz catalyst

Nov 18 22:28

$NGNE 241220 22.50C$ do you notice after trading in the 70+ range for over a year and having an insider sell off. theres some minor bad news but undercover probablymuch worse causing major players to remove there position. Then! you see this a buy offer for fail value price.
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money

Johnny Mnemonic

Nov 18 08:35

if it holds it will fall to 18.50

Stock_Drift

Nov 4 14:44

Unusual Volume Ticks close to close. 4:42pm

$Kazia Therapeutics (KZIA.US)$ $Disc Medicine (IRON.US)$ $Air Transport Services (ATSG.US)$ $Globalstar (GSAT.US)$ $Tenaya Therapeutics (TNYA.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Hanryu Holdings (HRYU.US)$ $Vast Renewables (VSTE.US)$ $Neurogene (NGNE.US)$ $Advent Technologies (ADN.US)$ $Staffing 360 Solutions (STAF.US)$ $Nuwellis (NUWE.US)$ $Simpple (SPPL.US)$
📊⚡️📊

Tarzanman™

Nov 4 11:28

$Neurogene (NGNE.US)$ this shud b 50 or less I'm shorting

Jaguar8

Apr 22 15:37

$Neurogene (NGNE.US)$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...